Personalis Earnings Call Transcripts
Fiscal Year 2026
-
Directors and auditors were elected and executive compensation was approved. The company highlighted strong test volume growth, successful reimbursement milestones, and ongoing AI integration, while addressing competitive challenges and maintaining a robust cash position.
-
Clinical test volumes surged 26% sequentially and 258% year-over-year, with Q1 revenue at $15.5M and strong physician adoption. Gross margin compressed to 1.8% due to strategic investments, but full-year guidance of $78–$80M is reaffirmed, with margin improvement expected in H2.
Fiscal Year 2025
-
Explosive clinical test growth and two Medicare coverage wins drove momentum in 2025, with 2026 guidance targeting $78–$80 million revenue and 43,000–45,000 clinical tests. Margin compression is expected to persist until further reimbursement, but strong cash reserves support aggressive expansion.
-
Q3 saw 4,388 clinical tests (up 26% sequentially, 364% year-over-year) and $14.5M revenue, with strong MRD adoption and three MolDX dossiers under review. Guidance was revised lower due to biopharma timing and reimbursement delays, but cash discipline remains strong.
-
Q2 2025 featured strong clinical growth and expanding physician adoption, but revenue declined 24% year-over-year due to biopharma project delays. Full-year guidance was lowered to $70M–$80M, with Medicare reimbursement for NeXT Personal expected to be a major catalyst.
-
Q1 2025 revenue grew 6% year-over-year to $20.6M, led by 39% biopharma growth and record clinical diagnostics. Guidance for 2025 is $80M–$90M revenue, with strong cash reserves and focus on reimbursement for key cancer indications.
Fiscal Year 2024
-
Full year 2024 revenue grew 15% to $84.6M, driven by 60% biopharma growth, while clinical test volumes rose 52% sequentially in Q4. Strategic partnerships, strong liquidity, and progress toward Medicare reimbursement position the company for continued growth in 2025.
-
Q3 2024 revenue rose 41% year-over-year to $25.7M, driven by biopharma and VA MVP growth, with strong adoption of NeXT Personal and a 68% sequential increase in clinical test volume. Gross margin improved to 34%, and cash runway extends into 2027. Full-year revenue guidance was raised to $83–$84M.
-
Q2 2024 revenue rose 35% year-over-year to $22.6 million, driven by strong biopharma and MRD growth. Full-year guidance increased to $79-81 million, with expanding margins and a solid cash position. Strategic partnerships and clinical data support continued momentum.
-
Ultra-sensitive ctDNA detection enables earlier and more accurate monitoring of cancer recurrence and response to immunotherapy, outperforming existing technologies in sensitivity and lead time. High specificity and broad applicability support its use in both escalation and de-escalation of therapy.